Floatz logo

Adv/Hsv-Tk

Lung Squamous Cell Carcinoma Stage IV

Eric Bernicker, MDgene_therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

47 Active assets in the Lung Squamous Cell Carcinoma Stage IV cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Hospital of Shandong University
Phase 4BBB
Carboplatin
zhang yi
Phase 3BBB
Docetaxel
Shanghai JMT-Bio Inc.
Phase 3BBB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 3BB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Adv/Hsv-Tk is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
Nonsquamous Nonsmall Cell Neoplasm of LungDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →